ResMed (RMD)

• Market cap: $35.2B
• 1 day: 1.12%
• 5 days: 3.57%
• 1 month: -1.17%
• 3 months: 0.08%
• 6 months: 16.43%
• Year to date: 4.95%
• 1 year: 40.46%
• 5 years: 49.33%
• 10 years: 298.17%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 10,140

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

50% more first-time investments, than exits

New positions opened: 108 | Existing positions closed: 72

23% more capital invested

Capital invested by funds: $17.2B [Q2] → $21.2B (+$4B) [Q3]

22% more repeat investments, than reductions

Existing positions increased: 312 | Existing positions reduced: 255

3% more funds holding

Funds holding: 757 [Q2] → 783 (+26) [Q3]

2.06% less ownership

Funds ownership: 61.34% [Q2] → 59.28% (-2.06%) [Q3]

58% less call options, than puts

Call options by funds: $258M | Put options by funds: $619M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $232 3% downside
• Avg. target: $257 7% upside
• High target: $283 18% upside

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target	5% upside $252	Neutral Initiated	10 Jan 2025
Stifel Jonathan Block 26% 1-year accuracy 5 / 19 met price target	4% upside $250	Hold Initiated	13 Dec 2024
RBC Capital Craig Wong-Pan 0 / 0 met price target	3% downside $232	Sector Perform Maintained	25 Oct 2024
Keybanc Brett Fishbin 55% 1-year accuracy 11 / 20 met price target	11% upside $266	Overweight Maintained	25 Oct 2024
Baird Joe Vruwink 40% 1-year accuracy 17 / 42 met price target	18% upside $283	Outperform Maintained	25 Oct 2024